IntelGenx Technologies Corp.

Good afternoon, ladies and gentlemen, and welcome to the Intelligenix First Quarter 2022 Financial Results Call. At this time, all participants have been placed on a listen-only mode, and the floor will be open for questions and comments after the presentation. It is now my pleasure to turn the floor over to your host, Abby Hardy, Investor Relations. Ma'am, the floor is yours.

Thank you, Operator. Good afternoon, everyone, and thank you for joining us on today's call. With me on the line are Dr. Horst Zerbe, IntelligenX CEO, Andre Godin, our president and CFO, and Dr. Dana Mattson, the company's vice president of business and corporate development. Before we begin, I would like to remind you that all amounts mentioned today are in U.S. dollars unless otherwise mentioned, and today's call may contain forward-looking information that represents our expectations as of today and accordingly are subject to change. We do not undertake any obligation to update any forward-looking statements, except as may be required by U.S. and Canadian securities laws. A number of assumptions were made by us in preparing these forward-looking statements, which are subject to risks, and results may differ materially. Details on these risks and assumptions can be found in our filings with the U.S. and Canadian Securities Commissions. I would now like to turn the call over to Dr. Zerbe. Horst?

Thank you, Abby. Good afternoon, everyone, and thank you for joining us for the Intertenix first quarter 2022 conference call. On today's call, I will provide a corporate update and discuss the progress we have made on our key pipeline projects. Then, Andre will review our first quarter 2022 financial results. Following that, we will open up the line for your questions. Although we continue to progress each of our development programs during the first quarter, today's corporate update will be brief. Our material news flow, which we expect would be heavier as the year progresses, was relatively light this quarter. So, first from the Atai partnership, in September, we entered into an amended and restated secured loan agreement with our partner, Atai Life Sciences. The loan committed $6 million in future financial support to Intergenix and helped us to meet certain requirements in conjunction with our uplisting for the TSX in October. During the first quarter of this year, we received our third term loan from Attai in the amount of $3 million, which we will use for working capital. Moving on to Resupport. We're meeting with Exceltis next week to discuss the internal analysis on commercializing in additional countries. On to Dalafil, there's no update at this time, certainly not from the last March investor call. Everything is progressing. Moving on to cannabis, we received an additional purchase order from Heritage for reselling our CB4 control film to one of the top three licensed producers in Canada. Montelukast, the resumption of patient enrollment and dosing in our Phase 2A Buena clinical trial in patients with mild to moderate Alzheimer's disease was definitely the highlight of the first quarter. The proof of concept study will assess Montelukast's versafilms safety, feasibility, tolerability, and efficacy for the treatment of mild to moderate Alzheimer's disease and is proceeding under the amended protocol with the higher daily dose that was previously cleared by Health Canada. In addition, we're in early discussions to expand the therapeutic use of Montelukast to COVID-19 and Parkinson's disease. Now moving on to animal health. We finalized the formulation development and completed a clinical batch for an undisclosed partner project. Again, the progress we continue to make is not reflected by this quarter's lighter news flow, which we expect will be a short-term trend. We look forward to updating you on our progress in the coming quarters. With that, I would now like to turn the call over to André for a review of our financial results. André?